ACST Stock – (NASDAQ: ACST) is giving an update on the usage
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is actually providing an update on the use of its “at the market” equity offering plan.
As previously disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. along with H.C. Wainwright & Co., LLC (collectively, the “Agents”), to carry out an “at-the market” equity offering program under which Acasti might issue and market from time to time the everyday shares of its having an aggregate offering price of up to seventy five dolars million in the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the end distributions reported on January 27, 2021, Acasti granted an aggregate of 20,159,229 typical shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 million. The ATM Shares ended up being marketed at prevailing market prices averaging US$1.0747 per share. No securities were marketed through the facilities of the TSXV or, to the expertise of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July 7, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with their services. As a consequence of the latest ATM sales, Acasti has a total of 200,119,659 common shares issued and great as of March 5, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and can supply the Company with more flexibility in its ongoing review process to enjoy and evaluate strategic options.
Approximately Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically concentrated on the research, commercialization and development of prescription medications using OM3 fatty acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, produced from krill oil. OM3 fatty acids have substantial clinical evidence of efficacy and safety in lowering triglycerides in patients with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being created for patients with serious HTG.
Forward Looking Statements – ACST Stock
Statements of that press release that aren’t statements of current or historical fact constitute “forward-looking information” to the meaning of Canadian securities laws as well as “forward looking statements” within the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward-looking assertions involve known and unknown risks, uncertainties, along with other unknown elements that might cause the particular outcomes of Acasti to be materially different from historical results and even from any future outcomes expressed or even implied by such forward looking statements. In addition to statements which explicitly describe these types of risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other related expressions to be forward-looking and uncertain. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the particular date of this particular press release. Forward-looking assertions in that press release include, but are not restricted to, info or statements about Acasti’s strategy, succeeding operations and the review of its of strategic options.
The forward-looking claims contained in this specific press release are expressly qualified in the entirety of theirs by this cautionary statement, the “Special Note Regarding Forward Looking Statements” section contained in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10-Q, which are readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and on the investor section of Acasti’s site at www.acastipharma.com. All forward looking assertions in this press release are produced as of the day of this press release.
ACST Stock – Acasti doesn’t undertake to upgrade any such forward-looking statements whether as a consequence of info which is brand new, future events or even otherwise, except as called for by law. The forward looking statements contained herein are also subject typically to assumptions and risks and uncertainties that are actually discussed from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, including Acasti’s newest annual report on Form 10 K and quarterly report on Form 10-Q underneath the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage